Core Insights - The transaction indicates a significant insider purchase by Srinivas Akkaraju, Director of Alumis, acquiring 588,235 shares for approximately $10.0 million, reflecting a strong belief in the company's future performance [5][6]. Company Overview - Alumis is a clinical-stage biotechnology company focused on developing therapies for autoimmune and neuroinflammatory diseases, leveraging advanced TYK2 inhibitor technology to address unmet medical needs [7]. Transaction Details - The shares were purchased at $17.00 each, which is below recent market prices, suggesting a favorable entry point for the insider [2][6]. - This acquisition is one of the largest recorded for Akkaraju, increasing his cumulative indirect holdings by nearly 47% in a single transaction [4][5]. Market Performance - Alumis' stock has appreciated significantly, with a 206.29% increase over the past year and over 400% in the last three months, indicating strong market confidence [5][8]. - The company recently reported successful phase 3 trial results for envudeucitinib, showing that 65% of patients achieved a 90% or better improvement in psoriasis severity scores [9]. Competitive Landscape - Alumis' psoriasis treatment candidate appears to be more effective than Amgen's Otezla, which had 33% of patients achieving a 75% improvement in similar trials [10].

Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its price target on the stock to $40 from $20, while maintaining a Buy rating on the shares. HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating The adjustment came after the company shared promising results earlier in the week from the Phase 3 ONWARD1 and ONWARD2 trials evaluating the efficacy of envudeucitinib in patients with moderate t ...

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis ...

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [5] Public Offering Details - Alumis announced an upsized underwritten public offering of 17,650,000 shares of common stock priced at $17.00 per share, aiming for gross proceeds of approximately $300.0 million [1] - The offering is expected to close on January 9, 2026, subject to customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 2,647,500 shares at the public offering price [2] Pipeline and Product Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [5] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease [5]

Key Takeaways ALMS surged 95.3% after envudeucitinib met all endpoints in two phase III plaque psoriasis studies.Envudeucitinib delivered strong PASI and sPGA skin clearance results in moderate-to-severe plaque psoriasis.ALMS plans to submit an NDA to the FDA for envudeucitinib in plaque psoriasis in 2H 2026.Shares of Alumis (ALMS) surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III studies — ONWARD1 and ONWARD2 — which evaluated its pipeline candidate, envudeuc ...

Alumis (ALMS) stock exploded higher on Tuesday after the biotech firm reported promising Phase 3 results for envudeucitinib, its candidate treatment for psoriasis. In the late-stage trial, envudeucitinib helped patients experience symptom improvement that “rank among the strongest reported for an oral therapy,” the company said in its press release. More News from Barchart While ALMS shares reversed nearly half of their intraday gains by market close on Jan. 6, at one point, they were seen trading at a ...

Alumis Inc. ( ALMS ) saw some massive stock movement yesterday, closing at gains of 95%. This was, of course, due to some very promising results from their lead candidate, envudeucitinib. The company also saw the result announcement as a goodI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation g ...

On Tuesday, U.S. stocks experienced a positive trading session. The Dow Jones Industrial Average climbed over 480 points, marking a 0.99% increase to 49,462.08. The NASDAQ also saw gains, rising 0.65% to 23,547.17, while the S&P 500 increased by 0.62% to 6,944.82.These are the top stocks that gained the attention of retail traders and investors throughout the day.SanDisk Corporation (NASDAQ:SNDK)SanDisk shares soared by 27.56%, closing at $349.63. The stock reached an intraday high of $352 and a low of $288 ...

Core Viewpoint - Alumis Inc. is a biopharmaceutical company focused on developing therapies for immune-mediated diseases, currently in late-stage clinical trials for moderate-to-severe plaque psoriasis with its drug envudeucitinib [1] Group 1: Stock Performance - The stock for ALMS is currently priced at $15.90, reflecting a significant increase of 91.33% with a change of $7.59 [3] - The stock has fluctuated between a low of $15.47 and a high of $22.30, marking its highest price over the past year, with the lowest price being $2.76 [3][6] - Derek Archila from Wells Fargo set a new price target for ALMS at $39, indicating a potential upside of 70.16% from its trading price of approximately $16.97 at the time [2][6] Group 2: Market Position - Alumis has a market capitalization of approximately $1.66 billion, reflecting its position in the biopharmaceutical industry [4][6] - The trading volume for the day is 53.93 million shares on the NASDAQ exchange, indicating heightened activity and interest in the stock [4][6] Group 3: Clinical Program - The announcement of the Phase 3 ONWARD clinical program results is a significant milestone for Alumis, with a conference call and webcast scheduled to discuss the results [5]

Alumis (NASDAQ:ALMS), which develops targeted therapies for immune-mediated diseases, closed Tuesday’s session at $16.23, up 95.31%. Trading volume reached 64.1 million shares, coming in about 3,077% above its three-month average of 2 million shares.Tuesday's move followed Phase 3 psoriasis data for envudeucitinib, which investors are treating as a potential commercial inflection point. The focus is now watching New Drug Application (NDA) timing and competitive dynamics in oral TYK2 inhibitors. How the ma ...